Terms ending in 2035
Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,010,498 | Methods for Treatment of Amyotrophic Lateral Sclerosis with Follistatin Fusion Proteins In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 10,023,621 | Follistatin-Related Fusion Proteins In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 11,497,792 | Methods for Treatment of Duchenne Muscular Dystrophy with Follistatin Polypeptides In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 9,850,298 | Methods for Treating Ulcers in Thalassemia Syndrome with an Actriib Polypeptide In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 10,487,144 | Methods for Treating Ulcers in a Hemoglobinopathy Anemia with a Soluble Actriib Polypeptide In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 11,260,107 | Methods and Compositions for Treating Ulcers In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 10,765,626 | Methods for Treatment of Charcot-Marie-Tooth Disease with Follistatin Polypeptides In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 10,954,279 | Methods and Compositions for Treatment of Disorders with Follistatin Polypeptides In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | |
| US 10,603,359 | Methods and Compositions Using GDF15 Polypeptides for Increasing Red Blood Cells In force · High confidence | Suragani, Rajasekhar Naga Venkata Sai | In force | High confidence | |
| US 11,642,394 | Methods and Compositions Using GDF15 Polypeptides for Increasing Red Blood Cells In force · Medium confidence | Suragani, Rajasekhar Naga Venkata Sai | In force | Medium confidence | |
| 2 more term ends in 2035 · Pro | |||||
10 of 12 patents shown. Soonest term end first, then patent number.
Pro members see all 12.
10 of these are in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.